Published on | 8 months ago
Programmes ERCThe final report and associated inventory of identified trusted repositories represent the output of a study conducted between September 2023 and September 2024 by an independent expert and commissioned by the European Research Council Executive Agency (ERCEA).
The research presented is meant to update the “Study on the readiness of research data and literature repositories to facilitate compliance with the Open Science Horizon Europe Model Grant Agreement (HE MGA) requirements”, published in 2023. In this study the experts assess and analyse the readiness of research data and literature repositories to facilitate compliance with the Open Science requirements, in particular regarding the metadata of deposited research outputs, in the Horizon Europe Model Grant Agreement.
The final report, the inventory of identified trusted repositories and questionnaire used to survey repository managers are publicly available on Zenodo. A summary of the findings can be found in the summary and conclusions in the final report (p.1-2; 27-28). The purpose of the study is explained in this ERC news article.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.